Inhibition of PARP in BRCA1 / 2 + or HRD-ovarian cancer

The experts reviewed the practical implications of the SOLO-1, PRIMA and VELIA trials and how to select a first-line treatment based on BRCA1 / 2 and HRD status.

---

Orignal From: Inhibition of PARP in BRCA1 / 2 + or HRD-ovarian cancer